Cooper Companies’ (COO) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Cooper Companies (NASDAQ:COO) in a research report report published on Friday,Benzinga reports.

Other research analysts have also issued research reports about the company. Robert W. Baird upped their price objective on Cooper Companies from $118.00 to $125.00 and gave the stock an “outperform” rating in a report on Thursday, August 29th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $115.00 price objective (up from $110.00) on shares of Cooper Companies in a research note on Thursday, August 29th. StockNews.com raised Cooper Companies from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd. Morgan Stanley lifted their price target on Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Tuesday, September 10th. Finally, Piper Sandler increased their price objective on shares of Cooper Companies from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, August 29th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus price target of $117.00.

Cooper Companies Trading Down 4.4 %

NASDAQ COO opened at $98.70 on Friday. The firm’s fifty day moving average price is $104.49 and its 200 day moving average price is $98.81. Cooper Companies has a 12 month low of $82.69 and a 12 month high of $112.38. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.99 and a quick ratio of 1.18. The company has a market capitalization of $19.66 billion, a price-to-earnings ratio of 50.62, a price-to-earnings-growth ratio of 2.28 and a beta of 0.97.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, December 5th. The medical device company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.04. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The firm’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.87 earnings per share. On average, sell-side analysts expect that Cooper Companies will post 4.03 earnings per share for the current fiscal year.

Insider Transactions at Cooper Companies

In related news, CEO Albert G. White III sold 114,992 shares of the company’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the completion of the sale, the chief executive officer now directly owns 165,273 shares of the company’s stock, valued at approximately $18,267,624.69. This represents a 41.03 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Agostino Ricupati sold 1,601 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $108.03, for a total value of $172,956.03. Following the completion of the transaction, the chief accounting officer now directly owns 4,818 shares in the company, valued at $520,488.54. This trade represents a 24.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.00% of the company’s stock.

Hedge Funds Weigh In On Cooper Companies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. LRI Investments LLC grew its holdings in Cooper Companies by 4.5% during the 2nd quarter. LRI Investments LLC now owns 2,595 shares of the medical device company’s stock worth $227,000 after acquiring an additional 112 shares in the last quarter. Mitchell & Pahl Private Wealth LLC grew its stake in Cooper Companies by 1.5% in the third quarter. Mitchell & Pahl Private Wealth LLC now owns 7,986 shares of the medical device company’s stock worth $881,000 after purchasing an additional 117 shares in the last quarter. Commonwealth Equity Services LLC grew its stake in Cooper Companies by 0.8% in the second quarter. Commonwealth Equity Services LLC now owns 15,600 shares of the medical device company’s stock worth $1,362,000 after purchasing an additional 118 shares in the last quarter. Bleakley Financial Group LLC raised its stake in Cooper Companies by 2.1% during the third quarter. Bleakley Financial Group LLC now owns 5,767 shares of the medical device company’s stock valued at $636,000 after buying an additional 119 shares in the last quarter. Finally, First Horizon Advisors Inc. lifted its holdings in Cooper Companies by 4.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 2,709 shares of the medical device company’s stock worth $236,000 after buying an additional 125 shares during the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.